Date: 2011-09-12
Type of information: Development agreement
Compound: novel microRNA therapeutics
Company: Silence Therapeutics (UK) InteRNA Technologies (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
Disease: cancer
Details: Silence Therapeutics and InteRNA Technologies have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer. This will combine the delivery capabilities of Silence’s proprietary AtuPLEX™ delivery system with InteRNA’s novel microRNAs. Under the terms of the agreement, InteRNA will provide Silence with specific miRNA sequences, which Silence will formulate with its AtuPLEX™ delivery system in order to develop multiple candidate drugs. Silence and InteRNA will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation.
Financial terms: Silence is eligible to receive upfront fees as well as staged research payments. Further financial terms of the deal were not disclosed.
Latest news:
